Taiwan's TWi gets FDA nod on Intuniv generic; Daiichi Sankyo looks home for growth;

> Taiwan's TWi Pharmaceutical received U.S. FDA approval for guanfacine tablets (Intuniv) and its marketing partner, Par Pharmaceutical, will launch the product in the U.S. Release

> China released a 2015 disease prevention and control report highlighting an overall stable situation in communicable diseases management since 2004. Report

> Astellas Pharma said Phase II data presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago showed the study met its primary endpoint. Release

> Daiichi Sankyo wants to re-organize R&D and boost sales in the home market ahead of the U.S. patent expiry for olmesartan next year. Report

> India has faced Human Serum Albumin shortages at hospitals in Mumbai for more than nine months blamed on price controls and a shortage of blood supply. Report

> A new way to target telomerase, an enzyme that is linked to 95% of all human cancers, has been discovered by researchers in Singapore. Report

> Glenmark's revenue growth in the year started April 1 of an estimated 20% is realistic, analysts said after the company reported full-year results. Report

> WuXi AppTec ($WX) will invest further into preclinical tech firm Instem and use the company's products at its newly built toxicology facility in Suzhou, China. Release

> A survey by Ernst & Young finds India's pharmaceutical industry struggling with pricing and regulatory issues from data integrity to good manufacturing, though still one of the most vibrant sectors in the domestic economy. Report

> India's Life Sciences sector suffers from poor management controls and data security as well as skilled workers, according to a survey by Deloitte. Report